Sciwind Biosciences Co., Ltd.

Industry

  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary

Other Names/Subsidiaries

  • Hangzhou Sciwind Biosciences Co., Ltd.
See more in Biomedtracker

Latest on Sciwind Biosciences Co., Ltd.

Scrip

Innogen’s Newly Approved GLP-1 Contender Girds For China Ozempic Battle

 
• By Dexter Jie Yan

A newly approved, homegrown once-weekly GLP-1 receptor agonist is seeking to disrupt a diabetes space in China currently dominated by Novo Nordisk’s same-class global blockbuster Ozempic (semaglutide)

Scrip

Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

 
• By Xu Hu

With some Phase III clinical and real-world evidence showing superior effects on HbA1c reduction in type 2 diabetes and on weight loss for GLP-1/GIP analogs, such as Eli Lilly and Company ’s tirzepat

Scrip

Deal Watch: AbbVie Pursues Novel Neuropsychiatric Drug Class With Gilgamesh

 
• By Joseph Haas, Vibha Ravi, and Lisa Takagi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie, Gilgamesh To Investigate Potent

Scrip

Asia Deal Watch: Astellas Seeks Pantherna’s Assistance On mRNA-Based Regenerative Medicine

 
• By Joseph Haas, Ian Haydock, and Jung Won Shin

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Astellas, Pantherna Expand mRNA Re